Literature DB >> 8519312

Phage typing of Vero cytotoxin-producing Escherichia coli O 157 isolated in the United Kingdom: 1989-91.

J A Frost1, T Cheasty, A Thomas, B Rowe.   

Abstract

Between 1989 and 1991 a total of 1092 Vero cytotoxin-producing Escherichia coli O 157 isolated in the United Kingdom were phage typed in the Laboratory of Enteric Pathogens (LEP). Twenty-three phage types was identified, the most frequent being types 2 (36.1%), 49 (29.6%), 1 (10.3%) and 4 (8.9%). Although isolations of O 157 VTEC have increased each year from 1 in 1982 to 532 in 1991, the predominant phage types have remained unchanged although the proportion of strains belonging to types 2 and 49 has increased. O 157 VTEC from 17 outbreaks were phage typed during this period with phage type 49 predominating (7 of 17 outbreaks).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8519312      PMCID: PMC2272298          DOI: 10.1017/s0950268800050895

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  16 in total

1.  Haemolytic-uraemic syndrome: clinical experience of an outbreak in the West Midlands.

Authors:  C M Taylor; R H White; M H Winterborn; B Rowe
Journal:  Br Med J (Clin Res Ed)       Date:  1986-06-07

2.  Phage-typing scheme for Escherichia coli O157:H7.

Authors:  R Ahmed; C Bopp; A Borczyk; S Kasatiya
Journal:  J Infect Dis       Date:  1987-04       Impact factor: 5.226

3.  Phage-typing of Vero-cytotoxin (VT) producing Escherichia coli O157 isolated in the United Kingdom.

Authors:  J A Frost; H R Smith; G A Willshaw; S M Scotland; R J Gross; B Rowe
Journal:  Epidemiol Infect       Date:  1989-08       Impact factor: 2.451

Review 4.  Illnesses associated with Escherichia coli O157:H7 infections. A broad clinical spectrum.

Authors:  P M Griffin; S M Ostroff; R V Tauxe; K D Greene; J G Wells; J H Lewis; P A Blake
Journal:  Ann Intern Med       Date:  1988-11-01       Impact factor: 25.391

5.  Heterogeneity of Escherichia coli phages encoding Vero cytotoxins: comparison of cloned sequences determining VT1 and VT2 and development of specific gene probes.

Authors:  G A Willshaw; H R Smith; S M Scotland; A M Field; B Rowe
Journal:  J Gen Microbiol       Date:  1987-05

6.  Vero cytotoxin-producing Escherichia coli O 157 in the United Kingdom.

Authors:  T Cheasty; A Thomas; H Chart; H R Smith; B Rowe
Journal:  Commun Dis Rep CDR Rev       Date:  1992-11-06

7.  Haemorrhagic colitis and Vero-cytotoxin-producing Escherichia coli in England and Wales.

Authors:  H R Smith; B Rowe; R J Gross; N K Fry; S M Scotland
Journal:  Lancet       Date:  1987-05-09       Impact factor: 79.321

8.  Vero response to a cytotoxin of Escherichia coli.

Authors:  J Konowalchuk; J I Speirs; S Stavric
Journal:  Infect Immun       Date:  1977-12       Impact factor: 3.441

9.  Vero cytotoxin-producing strains of Escherichia coli from children with haemolytic uraemic syndrome and their detection by specific DNA probes.

Authors:  S M Scotland; B Rowe; H R Smith; G A Willshaw; R J Gross
Journal:  J Med Microbiol       Date:  1988-04       Impact factor: 2.472

Review 10.  Infection by verocytotoxin-producing Escherichia coli.

Authors:  M A Karmali
Journal:  Clin Microbiol Rev       Date:  1989-01       Impact factor: 26.132

View more
  10 in total

1.  Use of the flagellar H7 gene as a target in multiplex PCR assays and improved specificity in identification of enterohemorrhagic Escherichia coli strains.

Authors:  V P Gannon; S D'Souza; T Graham; R K King; K Rahn; S Read
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

2.  Rapid genotyping of Escherichia coli O157 isolates by random amplification of polymorphic DNA.

Authors:  M Birch; D W Denning; D Law
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-04       Impact factor: 3.267

3.  RAPD (arbitrary primer) PCR is more sensitive than multilocus enzyme electrophoresis for distinguishing related bacterial strains.

Authors:  G Wang; T S Whittam; C M Berg; D E Berg
Journal:  Nucleic Acids Res       Date:  1993-12-25       Impact factor: 16.971

4.  Hybridization of strains of Escherichia coli O157 with probes derived from the eaeA gene of enteropathogenic E. coli and the eaeA homolog from a Vero cytotoxin-producing strain of E. coli O157.

Authors:  G A Willshaw; S M Scotland; H R Smith; T Cheasty; A Thomas; B Rowe
Journal:  J Clin Microbiol       Date:  1994-04       Impact factor: 5.948

Review 5.  Diarrheagenic Escherichia coli.

Authors:  J P Nataro; J B Kaper
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

6.  Outbreak of STEC O157:H7 linked to a milk pasteurisation failure at a dairy farm in England, 2019.

Authors:  Claire Jenkins; Philippa K Bird; Adrian Wensley; Jarrod Wilkinson; Heather Aird; Adrienne Mackintosh; David R Greig; Alex Simpson; Lisa Byrne; Rachel Wilkinson; Gauri Godbole; Nachi Arunachalam; Gareth J Hughes
Journal:  Epidemiol Infect       Date:  2022-05-18       Impact factor: 4.434

7.  Characterization of verocytotoxin-producing Escherichia coli O157 isolates from patients with haemolytic uraemic syndrome in Western Europe.

Authors:  A E Heuvelink; N C van de Kar; J F Meis; L A Monnens; W J Melchers
Journal:  Epidemiol Infect       Date:  1995-08       Impact factor: 2.451

8.  Use of digoxigenin-labelled oligonucleotide DNA probes for VT2 and VT2 human variant genes to differentiate Vero cytotoxin-producing Escherichia coli strains of serogroup O157.

Authors:  A Thomas; H R Smith; B Rowe
Journal:  J Clin Microbiol       Date:  1993-07       Impact factor: 5.948

9.  Vero cytotoxin-producing Escherichia coli, particularly serogroup O 157, associated with human infections in the United Kingdom: 1989-91.

Authors:  A Thomas; H Chart; T Cheasty; H R Smith; J A Frost; B Rowe
Journal:  Epidemiol Infect       Date:  1993-06       Impact factor: 2.451

10.  Sporadic isolates of Escherichia coli O157.H7 investigated by pyrolysis mass spectrometry.

Authors:  R Freeman; P R Sisson; D R Jenkins; A C Ward; N F Lightfoot; S J O'Brien
Journal:  Epidemiol Infect       Date:  1995-06       Impact factor: 2.451

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.